---
layout: default
title: Omalizumab
description: "Omalizumab çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 117
evidence_level: L1
indication_count: 10
---

# Omalizumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Omalizumabï¼šå¾ éæ•æ€§æ°£å–˜ åˆ° æ”¯æ°£ç®¡ç‚èˆ‡ç•°ä½æ€§çš®è†šç‚

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Omalizumab å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Omalizumabï¼ˆå–œç‘æ¨‚ï¼‰æ˜¯ä¸€ç¨®æŠ— IgE å–®æ ªæŠ—é«”ï¼Œç”¨æ–¼æ²»ç™‚é‡åº¦éæ•æ€§æ°£å–˜å’Œæ…¢æ€§è•éº»ç–¹ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå°**æ”¯æ°£ç®¡ç‚ (bronchitis)** å’Œ**ç•°ä½æ€§çš®è†šç‚ (atopic eczema)** æœ‰æ½›åœ¨æ²»ç™‚æ•ˆæœï¼Œç›®å‰æœ‰å¤šé …è‡¨åºŠè©¦é©—å’Œæ–‡ç»æ”¯æŒé€™äº›é æ¸¬ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | é‡åº¦éæ•æ€§æ°£å–˜ã€æ…¢æ€§é¼»ç«‡ç‚ä½µé¼»æ¯è‚‰ã€æ…¢æ€§è‡ªç™¼æ€§è•éº»ç–¹ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | bronchitisã€atopic eczemaã€obstructive lung diseaseã€allergic asthmaã€çš®è†šç‚ã€intrinsic asthmaã€bronchial neoplasm (disease)ã€acne keloidã€acrodermatitis chronica atrophicansã€hydroa vacciniforme, familial |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.99% (æ”¯æ°£ç®¡ç‚), 99.97% (ç•°ä½æ€§çš®è†šç‚) |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 2 å¼µ |
| å»ºè­°æ±ºç­– | Explore |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. bronchitis</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">100.00%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>Omalizumab é€šéèˆ‡æ¸¸é›¢ IgE çµåˆï¼Œé˜»æ­¢ IgE èˆ‡è‚¥å¤§ç´°èƒå’Œå—œé¹¼æ€§çƒä¸Šçš„é«˜è¦ªå’ŒåŠ›å—é«”ï¼ˆFcÎµRIï¼‰çµåˆï¼Œå¾è€ŒæŠ‘åˆ¶éæ•æ€§ç‚ç—‡åæ‡‰ã€‚</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02049294" target="_blank">NCT02049294</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>11</td><td>Randomized Double Blind Placebo Controlled Trial of the Steroid Sparing Effect o...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02477332" target="_blank">NCT02477332</a></td><td>PHASE2</td><td>COMPLETED</td><td>382</td><td>A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16222080/" target="_blank">16222080</a></td><td>2005</td><td>Article</td><td>Clinical reviews in allergy &amp; </td><td>Omalizumab in asthma: approval and postapproval experience.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21121874/" target="_blank">21121874</a></td><td>2011</td><td>Article</td><td>Current medical research and o</td><td>Safety and tolerability of omalizumab in children with allergic (IgE-mediated) a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30196731/" target="_blank">30196731</a></td><td>2018</td><td>Article</td><td>Expert opinion on pharmacother</td><td>Challenges in the management of asthma associated with smoking-induced airway di...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35369622/" target="_blank">35369622</a></td><td>2022</td><td>Article</td><td>Postepy dermatologii i alergol</td><td>Omalizumab in middle-aged or older patients with severe allergic asthma-COPD ove...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17663923/" target="_blank">17663923</a></td><td>2007</td><td>Article</td><td>Allergologia et immunopatholog</td><td>Monoclonal antibodies in pediatrics: use in prevention and treatment.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21163396/" target="_blank">21163396</a></td><td>2010</td><td>Article</td><td>Revue des maladies respiratoir</td><td>[Adult asthma exacerbations in questions].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31478531/" target="_blank">31478531</a></td><td>2019</td><td>Article</td><td>Journal of investigational all</td><td>A Rare Case of Plastic Bronchitis Following Bronchial Thermoplasty.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26466493/" target="_blank">26466493</a></td><td>2015</td><td>Article</td><td>Masui. The Japanese journal of</td><td>[Preoperative Management of Patients with Bronchial Asthma or Chronic Bronchitis...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. atopic eczema</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ18 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04037176" target="_blank">NCT04037176</a></td><td>PHASE4</td><td>COMPLETED</td><td>20</td><td>Treatment With Omalizumab in Food Allergic Children (TOFAC)</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05564221" target="_blank">NCT05564221</a></td><td>PHASE1</td><td>COMPLETED</td><td>46</td><td>A Randomized, Double-Blind, Placebo/Active Controlled, Multiple Ascending Dose, ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04060550" target="_blank">NCT04060550</a></td><td>N/A</td><td>UNKNOWN</td><td>36</td><td>Investigate the Impact of Increased IgE on Innate Anti-herpes Simplex Virus 1 Re...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05674695" target="_blank">NCT05674695</a></td><td>N/A</td><td>RECRUITING</td><td>2500</td><td>Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis The...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01179529" target="_blank">NCT01179529</a></td><td>PHASE2</td><td>COMPLETED</td><td>N/A</td><td>Single- Arm Trial to Identify Potential Markers Underlying Variability in Respon...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00367016" target="_blank">NCT00367016</a></td><td>PHASE4</td><td>COMPLETED</td><td>6</td><td>Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02300701" target="_blank">NCT02300701</a></td><td>PHASE4</td><td>COMPLETED</td><td>62</td><td>The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paedi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01678092" target="_blank">NCT01678092</a></td><td>PHASE1</td><td>COMPLETED</td><td>8</td><td>Phase 1, Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04535817" target="_blank">NCT04535817</a></td><td>PHASE1</td><td>WITHDRAWN</td><td>0</td><td>The Effect of Omalizumab (Xolair) on Improving Neuropsychiatric Symptoms in a Su...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01544348" target="_blank">NCT01544348</a></td><td>PHASE1</td><td>COMPLETED</td><td>295</td><td>A Phase 1 Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00822783" target="_blank">NCT00822783</a></td><td>PHASE4</td><td>COMPLETED</td><td>N/A</td><td>An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanist...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03964051" target="_blank">NCT03964051</a></td><td>PHASE4</td><td>TERMINATED</td><td>7</td><td>Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00123630" target="_blank">NCT00123630</a></td><td>PHASE2</td><td>COMPLETED</td><td>30</td><td>A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04763447" target="_blank">NCT04763447</a></td><td>PHASE4</td><td>RECRUITING</td><td>234</td><td>Impact of Omalizumab Withdrawal After a 3 Year Duration Treatment in Well Contro...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01995747" target="_blank">NCT01995747</a></td><td>N/A</td><td>COMPLETED</td><td>52</td><td>The Effect of Humanized Anti-CÎµmX Antibody (h4B12) on IgE Production in the PBMC...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04680117" target="_blank">NCT04680117</a></td><td>NA</td><td>UNKNOWN</td><td>150</td><td>Defining the Severe Paediatric Asthma Endotype: an Integrated Approach Combining...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05031455" target="_blank">NCT05031455</a></td><td>PHASE2</td><td>RECRUITING</td><td>16</td><td>Mechanisms of Dupilumab in AERD - Effects on Aspirin Hypersensitivity Response, ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07021495" target="_blank">NCT07021495</a></td><td>N/A</td><td>RECRUITING</td><td>840</td><td>A Prospective, Multi-Center, Observational Biomarker Real-World Evidence Study f...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35980214/" target="_blank">35980214</a></td><td>2022</td><td>Article</td><td>Journal of the European Academ</td><td>European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36878860/" target="_blank">36878860</a></td><td>2023</td><td>Article</td><td>International forum of allergy</td><td>International consensus statement on allergy and rhinology: Allergic rhinitis - ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36411004/" target="_blank">36411004</a></td><td>2023</td><td>Article</td><td>Immunology and allergy clinics</td><td>Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Derm...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39600395/" target="_blank">39600395</a></td><td>2024</td><td>Article</td><td>Allergologie select</td><td>Biologics in allergology and clinical immunology: Update on therapies for atopic...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38812522/" target="_blank">38812522</a></td><td>2024</td><td>Article</td><td>Frontiers in immunology</td><td>Effectiveness and safety of systemic therapy for moderate-to-severe atopic derma...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36355314/" target="_blank">36355314</a></td><td>2023</td><td>Article</td><td>Dermatology and therapy</td><td>The Combination of Dupilumab with Other Monoclonal Antibodies.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29438602/" target="_blank">29438602</a></td><td>2018</td><td>Article</td><td>International forum of allergy</td><td>International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31764954/" target="_blank">31764954</a></td><td>2020</td><td>Article</td><td>JAMA pediatrics</td><td>Omalizumab for Atopic Dermatitis: Overtreatment or Lifesaver?</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30717578/" target="_blank">30717578</a></td><td>2019</td><td>Article</td><td>Giornale italiano di dermatolo</td><td>Omalizumab for atopic dermatitis: evidence for and against its use.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33710614/" target="_blank">33710614</a></td><td>2021</td><td>Article</td><td>The Cochrane database of syste</td><td>Biologics for chronic rhinosinusitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35987486/" target="_blank">35987486</a></td><td>2022</td><td>Article</td><td>The journal of allergy and cli</td><td>Safety of Biologics for Atopic Diseases During Pregnancy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38488239/" target="_blank">38488239</a></td><td>2024</td><td>Article</td><td>Otolaryngology--head and neck </td><td>Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39158477/" target="_blank">39158477</a></td><td>2024</td><td>Article</td><td>Immunological reviews</td><td>Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarm...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37854067/" target="_blank">37854067</a></td><td>2023</td><td>Article</td><td>Allergologie select</td><td>Diagnosis and treatment of Hymenoptera venom allergy: S2k Guideline of the Germa...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40097336/" target="_blank">40097336</a></td><td>2025</td><td>Article</td><td>International journal of derma</td><td>Evidence-Based Recommendations for Managing Atopic Dermatitis in Pediatric Patie...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38908432/" target="_blank">38908432</a></td><td>2024</td><td>Article</td><td>Annals of allergy, asthma &amp; im</td><td>Atopic dermatitis and IgE-mediated food allergy: Common biologic targets for the...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27759482/" target="_blank">27759482</a></td><td>2017</td><td>Article</td><td>The Journal of dermatological </td><td>Dermatologic uses of omalizumabtitle.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33074565/" target="_blank">33074565</a></td><td>2021</td><td>Article</td><td>Allergy</td><td>Systemic treatments in the management of atopic dermatitis: A systematic review ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33310179/" target="_blank">33310179</a></td><td>2021</td><td>Article</td><td>Annals of allergy, asthma &amp; im</td><td>Traditional Chinese medicine for food allergy and eczema.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39413330/" target="_blank">39413330</a></td><td>2024</td><td>Article</td><td>Cutis</td><td>Does Omalizumab Cause Atopic Dermatitis Flare-Ups?</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. obstructive lung disease</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ50 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00624832" target="_blank">NCT00624832</a></td><td>PHASE4</td><td>COMPLETED</td><td>60</td><td>A Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00286416" target="_blank">NCT00286416</a></td><td>NA</td><td>UNKNOWN</td><td>60</td><td>Double Blind Study to Determine Effect of Omalizumab Treatment in Patients With ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00870584" target="_blank">NCT00870584</a></td><td>PHASE4</td><td>COMPLETED</td><td>271</td><td>A 26-week Randomized, Double-blind, Placebo-controlled, Multi-center Study to Ev...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04998604" target="_blank">NCT04998604</a></td><td>PHASE4</td><td>COMPLETED</td><td>360</td><td>A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizum...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01584687" target="_blank">NCT01584687</a></td><td>PHASE4</td><td>UNKNOWN</td><td>6</td><td>mRNA Expression as a Biomarker of Xolair (Omalizumab) Response</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00189228" target="_blank">NCT00189228</a></td><td>NA</td><td>COMPLETED</td><td>18</td><td>Not a Drug Trial. We Are Using Anti-IgE to Examine the Role of Pulmonary Mast Ce...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00208234" target="_blank">NCT00208234</a></td><td>PHASE4</td><td>UNKNOWN</td><td>22</td><td>The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00133042" target="_blank">NCT00133042</a></td><td>PHASE4</td><td>COMPLETED</td><td>16</td><td>The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05270278" target="_blank">NCT05270278</a></td><td>N/A</td><td>COMPLETED</td><td>89</td><td>Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomar...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06261567" target="_blank">NCT06261567</a></td><td>N/A</td><td>COMPLETED</td><td>415</td><td>A Retrospective Chart Review to Investigate Clinical Remission in Patients With ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00314574" target="_blank">NCT00314574</a></td><td>PHASE3</td><td>COMPLETED</td><td>850</td><td>A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00777764" target="_blank">NCT00777764</a></td><td>PHASE4</td><td>COMPLETED</td><td>60</td><td>The Safety and Utility of Skin Testing With XOLAIRÂ® (Omalizumab) and Placebo Oma...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00482248" target="_blank">NCT00482248</a></td><td>PHASE3</td><td>COMPLETED</td><td>132</td><td>An Open-label Extension Study to Assess Long Term Safety and Tolerability of Oma...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00377390" target="_blank">NCT00377390</a></td><td>N/A</td><td>COMPLETED</td><td>224</td><td>Inner-City Anti-IgE Therapy for Asthma Mechanistic Study</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05157087" target="_blank">NCT05157087</a></td><td>N/A</td><td>COMPLETED</td><td>16246</td><td>XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00079937" target="_blank">NCT00079937</a></td><td>PHASE3</td><td>COMPLETED</td><td>628</td><td>A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicen...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00401596" target="_blank">NCT00401596</a></td><td>PHASE3</td><td>COMPLETED</td><td>1899</td><td>A Multicenter, Randomized, Controlled, Open-Label Study to Evaluate the Safety o...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01397760" target="_blank">NCT01397760</a></td><td>N/A</td><td>UNKNOWN</td><td>20</td><td>Retrospective Study for Description of The Use Of Omalizumab In Patients With Di...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00232050" target="_blank">NCT00232050</a></td><td>PHASE3</td><td>COMPLETED</td><td>327</td><td>Study of Omalizumab in Moderate to Severe Bronchial Asthma</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00670930" target="_blank">NCT00670930</a></td><td>PHASE4</td><td>COMPLETED</td><td>36</td><td>A Randomized, Multi-center, Double-blind, Placebo-controlled, Parallel-group Tri...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00329381" target="_blank">NCT00329381</a></td><td>PHASE4</td><td>COMPLETED</td><td>14</td><td>A26-wk,Randomized,Dble-Blinded,Parallel-Grp,Placebo-Controlled,Multi-Centered St...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03727971" target="_blank">NCT03727971</a></td><td>PHASE2</td><td>COMPLETED</td><td>66</td><td>Use of Omalizumab Will Increase the Pregnancy Rate, Proof of Concept Study, Wher...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05792592" target="_blank">NCT05792592</a></td><td>N/A</td><td>UNKNOWN</td><td>54</td><td>Small Airways Disease (SAD) in Severe Asthma as a Novel Endpoint and Distinct Ta...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00639691" target="_blank">NCT00639691</a></td><td>PHASE4</td><td>COMPLETED</td><td>48</td><td>A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab)in ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06869382" target="_blank">NCT06869382</a></td><td>PHASE4</td><td>COMPLETED</td><td>26</td><td>Comparative Analysis of ICS Combined with LABA Versus Addition of Omalizumab on ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01202903" target="_blank">NCT01202903</a></td><td>PHASE3</td><td>COMPLETED</td><td>616</td><td>A 24-week, Phase III Randomized, Double-blind, Placebocontrolled, Parallel-group...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00046748" target="_blank">NCT00046748</a></td><td>PHASE3</td><td>COMPLETED</td><td>484</td><td>Ph III, 28-wk, Multicenter, Randomized, Double-blind, Placebo-controlled, Parall...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00180011" target="_blank">NCT00180011</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>18</td><td>Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01976208" target="_blank">NCT01976208</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>630</td><td>A Multicenter, Randomized, Double-blinded, Placebo-controlled Clinical Study to ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00546143" target="_blank">NCT00546143</a></td><td>PHASE4</td><td>COMPLETED</td><td>32</td><td>Multi-center, Open-label, Multiple Dose Study in Mild to Moderate Asthmatics (Wi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06456450" target="_blank">NCT06456450</a></td><td>N/A</td><td>RECRUITING</td><td>500</td><td>Taiwan Severe Asthma Biologic Registry</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01430403" target="_blank">NCT01430403</a></td><td>PHASE4</td><td>COMPLETED</td><td>478</td><td>Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (ICAC-2...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06024707" target="_blank">NCT06024707</a></td><td>N/A</td><td>UNKNOWN</td><td>48</td><td>Early Detection of the Effectiveness of Treatment With Biologicals in Patients W...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01219036" target="_blank">NCT01219036</a></td><td>NA</td><td>COMPLETED</td><td>40</td><td>The Use of Fractional Exhaled Nitric Oxide (FeNO) and Induced Sputum in the Iden...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00434434" target="_blank">NCT00434434</a></td><td>PHASE2</td><td>COMPLETED</td><td>61</td><td>A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Contr...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00109187" target="_blank">NCT00109187</a></td><td>PHASE3</td><td>COMPLETED</td><td>0</td><td>Open-Label Extension Study II of Xolair (Omalizumab) in Moderate to Severe, Pers...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00367016" target="_blank">NCT00367016</a></td><td>PHASE4</td><td>COMPLETED</td><td>6</td><td>Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00567476" target="_blank">NCT00567476</a></td><td>PHASE4</td><td>COMPLETED</td><td>116</td><td>A Randomized, Open-label, Multicenter Study to Evaluate the Effect of Xolair (Om...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04607629" target="_blank">NCT04607629</a></td><td>PHASE3</td><td>COMPLETED</td><td>192</td><td>A Comparative Study of Efficacy and Safety of GenolarÂ® and XolarÂ® in Treating Pa...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00784485" target="_blank">NCT00784485</a></td><td>PHASE4</td><td>TERMINATED</td><td>13</td><td>Non-Invasive Measures of Distal Lung Disease in Asthmatics Before and After Trea...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02293265" target="_blank">NCT02293265</a></td><td>PHASE3</td><td>COMPLETED</td><td>767</td><td>Identification and Description of Severe Asthma Patients in a Cross-sectional St...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00219323" target="_blank">NCT00219323</a></td><td>PHASE3</td><td>COMPLETED</td><td>133</td><td>Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03476109" target="_blank">NCT03476109</a></td><td>PHASE4</td><td>UNKNOWN</td><td>100</td><td>Predictive Factors and Magnitude of Response to Omalizumab and Mepolizumab in Al...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00813748" target="_blank">NCT00813748</a></td><td>N/A</td><td>COMPLETED</td><td>118</td><td>Pharmacosurveillance Data Repository of Patients With and Without History of Ana...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00096954" target="_blank">NCT00096954</a></td><td>PHASE4</td><td>COMPLETED</td><td>333</td><td>A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xol...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05001529" target="_blank">NCT05001529</a></td><td>PHASE4</td><td>UNKNOWN</td><td>80</td><td>Flow Cytometry Analysis of Eosinophils Activity and Membrane Receptors Expressio...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01449409" target="_blank">NCT01449409</a></td><td>NA</td><td>ACTIVE_NOT_RECRUITING</td><td>3000</td><td>Reduce IDentified UNcontrolled Asthma: A Real-time Randomized Administrative Out...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01393340" target="_blank">NCT01393340</a></td><td>PHASE2</td><td>COMPLETED</td><td>23</td><td>Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilate...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00495612" target="_blank">NCT00495612</a></td><td>PHASE4</td><td>COMPLETED</td><td>69</td><td>A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Study o...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01460862" target="_blank">NCT01460862</a></td><td>N/A</td><td>WITHDRAWN</td><td>0</td><td>Analyze the Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits an...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36740144/" target="_blank">36740144</a></td><td>2023</td><td>Article</td><td>The Journal of allergy and cli</td><td>Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37869947/" target="_blank">37869947</a></td><td>2023</td><td>Article</td><td>European review for medical an</td><td>Biologics in allergic rhinitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36581073/" target="_blank">36581073</a></td><td>2023</td><td>Article</td><td>The journal of allergy and cli</td><td>Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and M...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39186985/" target="_blank">39186985</a></td><td>2024</td><td>Article</td><td>The Journal of allergy and cli</td><td>Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41033334/" target="_blank">41033334</a></td><td>2025</td><td>Article</td><td>The Lancet. Respiratory medici</td><td>Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal p...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11496232/" target="_blank">11496232</a></td><td>2001</td><td>Article</td><td>The Journal of allergy and cli</td><td>Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatmen...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31760132/" target="_blank">31760132</a></td><td>2020</td><td>Article</td><td>Annals of allergy, asthma &amp; im</td><td>Effect of omalizumab on lung function and eosinophil levels in adolescents with ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11270941/" target="_blank">11270941</a></td><td>2001</td><td>Article</td><td>Drugs</td><td>Omalizumab.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25404353/" target="_blank">25404353</a></td><td>2014</td><td>Article</td><td>Paediatric drugs</td><td>Omalizumab in children.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26075226/" target="_blank">26075226</a></td><td>2015</td><td>Article</td><td>BioMed research international</td><td>Advances in anti-IgE therapy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38235607/" target="_blank">38235607</a></td><td>2024</td><td>Article</td><td>Therapeutic advances in respir</td><td>Effects of omalizumab on lung function in patients with moderate-to-severe aller...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33160970/" target="_blank">33160970</a></td><td>2021</td><td>Article</td><td>The Journal of allergy and cli</td><td>Omalizumab in &quot;non-IgE-mediated&quot; diseases.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22264640/" target="_blank">22264640</a></td><td>2012</td><td>Article</td><td>Allergologia et immunopatholog</td><td>Omalizumab beyond asthma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31145939/" target="_blank">31145939</a></td><td>2020</td><td>Article</td><td>The Journal of allergy and cli</td><td>Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched co...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27824606/" target="_blank">27824606</a></td><td>2016</td><td>Article</td><td>The European respiratory journ</td><td>Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24477463/" target="_blank">24477463</a></td><td>2014</td><td>Article</td><td>Pneumologie (Stuttgart, German</td><td>[Disease modification and duration of omalizumab treatment in patients with seve...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38474304/" target="_blank">38474304</a></td><td>2024</td><td>Article</td><td>International journal of molec</td><td>The Incredible Adventure of Omalizumab.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26772933/" target="_blank">26772933</a></td><td>2016</td><td>Article</td><td>The journal of allergy and cli</td><td>Omalizumab and Allergic Reactions.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34384308/" target="_blank">34384308</a></td><td>2023</td><td>Article</td><td>Journal of pharmacy practice</td><td>Effectiveness and Safety Studies of Omalizumab in Children and Adolescents With ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28189435/" target="_blank">28189435</a></td><td>2017</td><td>Article</td><td>Revue des maladies respiratoir</td><td>[Omalizumab: Beyond anti-IgE properties].</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. dermatitis</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ19 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04037176" target="_blank">NCT04037176</a></td><td>PHASE4</td><td>COMPLETED</td><td>20</td><td>Treatment With Omalizumab in Food Allergic Children (TOFAC)</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05564221" target="_blank">NCT05564221</a></td><td>PHASE1</td><td>COMPLETED</td><td>46</td><td>A Randomized, Double-Blind, Placebo/Active Controlled, Multiple Ascending Dose, ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04060550" target="_blank">NCT04060550</a></td><td>N/A</td><td>UNKNOWN</td><td>36</td><td>Investigate the Impact of Increased IgE on Innate Anti-herpes Simplex Virus 1 Re...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05674695" target="_blank">NCT05674695</a></td><td>N/A</td><td>RECRUITING</td><td>2500</td><td>Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis The...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01179529" target="_blank">NCT01179529</a></td><td>PHASE2</td><td>COMPLETED</td><td>N/A</td><td>Single- Arm Trial to Identify Potential Markers Underlying Variability in Respon...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00367016" target="_blank">NCT00367016</a></td><td>PHASE4</td><td>COMPLETED</td><td>6</td><td>Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02300701" target="_blank">NCT02300701</a></td><td>PHASE4</td><td>COMPLETED</td><td>62</td><td>The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paedi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01678092" target="_blank">NCT01678092</a></td><td>PHASE1</td><td>COMPLETED</td><td>8</td><td>Phase 1, Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04535817" target="_blank">NCT04535817</a></td><td>PHASE1</td><td>WITHDRAWN</td><td>0</td><td>The Effect of Omalizumab (Xolair) on Improving Neuropsychiatric Symptoms in a Su...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01544348" target="_blank">NCT01544348</a></td><td>PHASE1</td><td>COMPLETED</td><td>295</td><td>A Phase 1 Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00822783" target="_blank">NCT00822783</a></td><td>PHASE4</td><td>COMPLETED</td><td>N/A</td><td>An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanist...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03964051" target="_blank">NCT03964051</a></td><td>PHASE4</td><td>TERMINATED</td><td>7</td><td>Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00123630" target="_blank">NCT00123630</a></td><td>PHASE2</td><td>COMPLETED</td><td>30</td><td>A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04763447" target="_blank">NCT04763447</a></td><td>PHASE4</td><td>RECRUITING</td><td>234</td><td>Impact of Omalizumab Withdrawal After a 3 Year Duration Treatment in Well Contro...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01995747" target="_blank">NCT01995747</a></td><td>N/A</td><td>COMPLETED</td><td>52</td><td>The Effect of Humanized Anti-CÎµmX Antibody (h4B12) on IgE Production in the PBMC...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04680117" target="_blank">NCT04680117</a></td><td>NA</td><td>UNKNOWN</td><td>150</td><td>Defining the Severe Paediatric Asthma Endotype: an Integrated Approach Combining...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05031455" target="_blank">NCT05031455</a></td><td>PHASE2</td><td>RECRUITING</td><td>16</td><td>Mechanisms of Dupilumab in AERD - Effects on Aspirin Hypersensitivity Response, ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07021495" target="_blank">NCT07021495</a></td><td>N/A</td><td>RECRUITING</td><td>840</td><td>A Prospective, Multi-Center, Observational Biomarker Real-World Evidence Study f...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00260702" target="_blank">NCT00260702</a></td><td>PHASE1</td><td>COMPLETED</td><td>1</td><td>Pilot Study of Omalizumab (Xolair) in Hyper IgE (Job&#x27;s) Syndrome</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30717578/" target="_blank">30717578</a></td><td>2019</td><td>Article</td><td>Giornale italiano di dermatolo</td><td>Omalizumab for atopic dermatitis: evidence for and against its use.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27337170/" target="_blank">27337170</a></td><td>2017</td><td>Article</td><td>International journal of derma</td><td>Omalizumab for atopic dermatitis: case series and a systematic review of the lit...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36878860/" target="_blank">36878860</a></td><td>2023</td><td>Article</td><td>International forum of allergy</td><td>International consensus statement on allergy and rhinology: Allergic rhinitis - ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36411004/" target="_blank">36411004</a></td><td>2023</td><td>Article</td><td>Immunology and allergy clinics</td><td>Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Derm...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35980214/" target="_blank">35980214</a></td><td>2022</td><td>Article</td><td>Journal of the European Academ</td><td>European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37988298/" target="_blank">37988298</a></td><td>2023</td><td>Article</td><td>Cutis</td><td>Atopic Dermatitis Triggered by Omalizumab and Treated With Dupilumab.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38812522/" target="_blank">38812522</a></td><td>2024</td><td>Article</td><td>Frontiers in immunology</td><td>Effectiveness and safety of systemic therapy for moderate-to-severe atopic derma...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27543070/" target="_blank">27543070</a></td><td>2016</td><td>Article</td><td>The Journal of allergy and cli</td><td>Efficacy of omalizumab in patients with atopic dermatitis: AÂ systematic review a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31998003/" target="_blank">31998003</a></td><td>2019</td><td>Article</td><td>Postepy dermatologii i alergol</td><td>Omalizumab usage in chronic urticaria and atopic dermatitis: data from South-Eas...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31764954/" target="_blank">31764954</a></td><td>2020</td><td>Article</td><td>JAMA pediatrics</td><td>Omalizumab for Atopic Dermatitis: Overtreatment or Lifesaver?</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29438602/" target="_blank">29438602</a></td><td>2018</td><td>Article</td><td>International forum of allergy</td><td>International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31233174/" target="_blank">31233174</a></td><td>2019</td><td>Article</td><td>Acta dermatovenerologica Alpin</td><td>Lack of omalizumab efficacy in severe atopic dermatitis with extremely elevated ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33710614/" target="_blank">33710614</a></td><td>2021</td><td>Article</td><td>The Cochrane database of syste</td><td>Biologics for chronic rhinosinusitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39158477/" target="_blank">39158477</a></td><td>2024</td><td>Article</td><td>Immunological reviews</td><td>Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarm...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36355314/" target="_blank">36355314</a></td><td>2023</td><td>Article</td><td>Dermatology and therapy</td><td>The Combination of Dupilumab with Other Monoclonal Antibodies.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34273058/" target="_blank">34273058</a></td><td>2021</td><td>Article</td><td>Clinical reviews in allergy &amp; </td><td>Current Perspectives on Severe Drug Eruption.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38488239/" target="_blank">38488239</a></td><td>2024</td><td>Article</td><td>Otolaryngology--head and neck </td><td>Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35987486/" target="_blank">35987486</a></td><td>2022</td><td>Article</td><td>The journal of allergy and cli</td><td>Safety of Biologics for Atopic Diseases During Pregnancy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40097336/" target="_blank">40097336</a></td><td>2025</td><td>Article</td><td>International journal of derma</td><td>Evidence-Based Recommendations for Managing Atopic Dermatitis in Pediatric Patie...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33074565/" target="_blank">33074565</a></td><td>2021</td><td>Article</td><td>Allergy</td><td>Systemic treatments in the management of atopic dermatitis: A systematic review ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. bronchial neoplasm (disease)</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.95%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ2 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06869382" target="_blank">NCT06869382</a></td><td>PHASE4</td><td>COMPLETED</td><td>26</td><td>Comparative Analysis of ICS Combined with LABA Versus Addition of Omalizumab on ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04680117" target="_blank">NCT04680117</a></td><td>NA</td><td>UNKNOWN</td><td>150</td><td>Defining the Severe Paediatric Asthma Endotype: an Integrated Approach Combining...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20955114/" target="_blank">20955114</a></td><td>2010</td><td>Article</td><td>Expert opinion on biological t</td><td>Omalizumab for pediatric asthma.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. acne keloid</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. acrodermatitis chronica atrophicans</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.93%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. hydroa vacciniforme, familial</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.93%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. neonatal dermatomyositis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.93%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. secondary interstitial lung disease specific to childhood associated with a connective tissue disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­— | å–œç‘æ¨‚å‡æ™¶æ³¨å°„åŠ‘150æ¯«å…‹ | æ³¨å°„åŠ‘ | é‡åº¦æŒçºŒéæ•æ€§æ°£å–˜ã€æ…¢æ€§é¼»ç«‡ç‚ä½µé¼»æ¯è‚‰ã€æ…¢æ€§è‡ªç™¼æ€§è•éº»ç–¹ |

## å®‰å…¨æ€§è€ƒé‡

**é‡è¦è­¦å‘Šï¼š**
- **éæ•æ€§åæ‡‰/Anaphylaxis**ï¼šç½•è¦‹ä½†å¯èƒ½è‡´å‘½ï¼Œå»ºè­°æ³¨å°„å¾Œè§€å¯Ÿ
- æ³¨å°„éƒ¨ä½åæ‡‰
- ç—…æ¯’æ„ŸæŸ“ï¼ˆä¸Šå‘¼å¸é“æ„ŸæŸ“ï¼‰
- é ­ç—›

**çµ¦è—¥é™åˆ¶ï¼š**
- éœ€æ ¹æ“šé«”é‡å’Œè¡€æ¸… IgE æ°´å¹³è¨ˆç®—åŠ‘é‡
- è¡€æ¸… IgE 30-1300 IU/mLï¼ˆæ°£å–˜é©æ‡‰ç—‡ï¼‰
- éœ€åœ¨é†«ç™‚å ´æ‰€çµ¦è—¥ä¸¦è§€å¯Ÿ

**ç•°ä½æ€§çš®è†šç‚æ³¨æ„ï¼š**
- è¨±å¤š AD æ‚£è€… IgE æ°´å¹³è¶…é 700 IU/mLï¼Œå¯èƒ½è¶…å‡ºå»ºè­°åŠ‘é‡ç¯„åœ
- è‡¨åºŠè©¦é©—çµæœä¸ä¸€è‡´


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Neoplasms** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šExplore**

**ç†ç”±ï¼š**
Omalizumab å°ç•°ä½æ€§çš®è†šç‚å’Œæ”¯æ°£ç®¡ç‚çš„é æ¸¬å…·æœ‰åˆç†çš„è—¥ç†å­¸åŸºç¤ï¼Œä¸”æœ‰å¤šé …è‡¨åºŠè©¦é©—æ¢ç´¢é€™äº›æ‡‰ç”¨ã€‚ç•°ä½æ€§çš®è†šç‚çš„è©¦é©—çµæœé¡¯ç¤ºéƒ¨åˆ†æ‚£è€…å—ç›Šï¼Œä½†ç™‚æ•ˆä¸ä¸€è‡´ï¼Œå¯èƒ½èˆ‡ IgE æ°´å¹³å’Œå…¶ä»–å› ç´ æœ‰é—œã€‚æ”¯æ°£ç®¡ç‚ï¼ˆç‰¹åˆ¥æ˜¯å—œé…¸æ€§çƒæ€§æ”¯æ°£ç®¡ç‚ï¼‰èˆ‡éæ•æ€§æ°£å–˜æœ‰é‡ç–Šæ©Ÿåˆ¶ï¼Œä½¿ç”¨ omalizumab å…·æœ‰åˆç†æ€§ã€‚

ç„¶è€Œï¼Œéœ€æ³¨æ„ï¼š
- Dupilumab å·²æˆç‚ºç•°ä½æ€§çš®è†šç‚çš„æ¨™æº–ç”Ÿç‰©è£½åŠ‘æ²»ç™‚
- æ”¯æ°£ç®¡ç‚ç—…å› å¤šæ¨£ï¼Œéæ‰€æœ‰é¡å‹éƒ½é©åˆæŠ— IgE æ²»ç™‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ˜ç¢ºå“ªäº›äºç¾¤æ‚£è€…æœ€å¯èƒ½å¾ omalizumab å—ç›Š
- èˆ‡ç¾æœ‰æ¨™æº–æ²»ç™‚ï¼ˆå¦‚ dupilumab for ADï¼‰çš„æ¯”è¼ƒç ”ç©¶
- é–‹ç™¼é æ¸¬æ²»ç™‚åæ‡‰çš„ç”Ÿç‰©æ¨™è¨˜
- è©•ä¼°é«˜ IgE æ°´å¹³æ‚£è€…ï¼ˆ>700 IU/mLï¼‰çš„åŠ‘é‡ç­–ç•¥

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Hydroxyurea]({{ "/drugs/hydroxyurea/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Oteracil]({{ "/drugs/oteracil/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Isosorbide Dinitrate]({{ "/drugs/isosorbide_dinitrate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Carboplatin]({{ "/drugs/carboplatin/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Omalizumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/omalizumab/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_omalizumab,
  title = {Omalizumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/omalizumab/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
